Search Results

You are looking at 251 - 260 of 490 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy

David D. Chism

paclitaxel, cisplatin, plus gemcitabine (PCG) triplet are also effective treatments based on median survivals of 14 and 16 months, respectively. 7 , 8 Dose-dense MVAC plus G-CSF, the GC doublet, and the PCG triplet are NCCN Clinical Practice Guidelines in

Full access

New NCCN Guidelines for Vulvar Cancer

Benjamin E. Greer and Wui-Jin Koh

, chemotherapy should include cisplatin, cisplatin/vinorelbine, or cisplatin/paclitaxel. “The site of the cancer matters,” said Wui-Jin Koh, MD, Professor at Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance and Co-Chair of the NCCN Vulvar

Full access

Evidence and Controversies in the Use of Post-Mastectomy Radiation

Shaneli A. Fernando and Stephen B. Edge

. 26. Burstein HJ Bellon JR Galper S . Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for stage II or III breast cancer . Int J Radiat Oncol Biol Phys 2006 ; 64

Full access

Anaplastic Classic Kaposi Sarcoma: PD-L1 Expression and Response to Immunotherapy: A Case Report and Review of the Literature

Ivan Lolli, Anna Maria Valentini, Angela Dalia Ricci, and Raffaele Armentano

lymphedema despite chemotherapy with pegylated liposomal doxorubicin (PLD; 20 mg/m 2 intravenously every 3 weeks) and paclitaxel (80 mg/m 2 intravenously every 3 weeks). Figure 1. (A) Cutaneous CKS (hematoxylin-eosin, original magnification ×40). (B

Full access

Predictive Molecular Markers: Has the Time Come for Routine Use in Lung Cancer?

Angela M. Davies, Philip C. Mack, Primo N. Lara Jr., Derick H. Lau, Kathleen Danenberg, Paul H. Gumerlock, and David R. Gandara

microtubules in mouse fibroblast cells . Proc Natl Acad Sci USA 1980 ; 77 : 1561 – 1565 . 16 Monzo M Rosell R Sanchez JJ . Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations . J Clin Oncol 1999 ; 17

Full access

Emerging Multimodality Approaches to Treat Localized Esophageal Cancer

Ronan J. Kelly

paclitaxel/carboplatin either alone or in addition to trastuzumab weekly for 7 doses before surgery and, beginning 21 to 56 days after esophagectomy, every 3 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. In the metastatic

Full access

Guideline Discordance and Patient Cost Responsibility in Medicare Beneficiaries With Metastatic Breast Cancer

Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia, and Gabrielle B. Rocque

mortality (hazard ratio, 1.40; 95% CI, 1.13–1.74). 5 However, this category did not include patients who received paclitaxel with bevacizumab, because this combination was included in the NCCN Guidelines during our study period based on its accelerated

Full access

Predictors of Locoregional Recurrence After Failure to Achieve Pathologic Complete Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Prashant Gabani, Emily Merfeld, Amar J. Srivastava, Ashley A. Weiner, Laura L. Ochoa, Dan Mullen, Maria A. Thomas, Julie A. Margenthaler, Amy E. Cyr, Lindsay L. Peterson, Michael J. Naughton, Cynthia Ma, and Imran Zoberi

age at diagnosis was 49.5 years (range, 28.8–77.3 years). The most common NAC regimen was doxorubicin/cyclophosphamide/paclitaxel (AC-T; n=62; 40.5%). Patients receiving epirubicin/paclitaxel (ET) were part of an institutional phase II trial. 11

Full access

Local Treatment of Malignant Brain Tumors Using Implantable Chemotherapeutic Polymers

Gary L. Gallia, Steven Brem, and Henry Brem

biocompatibility of a biodegradable, controlled-release polymer in rats . J Biomed Mater Res 1989 ; 23 : 253 – 266 . 10 Fung LK Ewend MG Sills A . Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel

Full access

Resurrection of PARP Inhibitors in Breast Cancer

Tomas G. Lyons and Mark E. Robson

study of single-agent veliparib showed a PFS of 5.2 months, with a response rate of 14% and 36% for patients with BRCA1 and BRCA2 mutations, respectively. 25 Results of combining veliparib with carboplatin and paclitaxel in the randomized phase II